Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, United States.
Neuropharmacology. 2011 Jul-Aug;61(1-2):245-51. doi: 10.1016/j.neuropharm.2011.04.007. Epub 2011 Apr 17.
Cocaine self-administration alters brain dopaminergic and serotonergic function primarily in mesolimbic and prefrontal brain regions whereas 3,4-methylenedioxymethamphetamine (MDMA) self-administration predominately alters brain serotonergic function in a more widespread distribution across cortical regions. We previously reported that, compared to drug-naïve rhesus monkeys, self-administration of cocaine but not MDMA was associated with increased serotonin transporter (SERT) availability in two mesolimbic regions, the caudate nucleus and putamen, as measured by positron emission tomography (PET) using the SERT-specific ligand [(11)C]-3-amino-4(2-dimethylamino-methyl-phenylsulfanyl)-benzonitrile ([(11)C]DASB). The goal of the present study was to extend this comparison between cocaine and MDMA self-administration to SERT availability in cortical regions, which have been shown previously to be affected in human drug abusers and are associated with executive function. PET studies using [(11)C]DASB were conducted in adult male rhesus monkeys with a history of cocaine (mean intake = 742.6 mg/kg) or MDMA (mean intake = 121.0 mg/kg) self-administration, and drug-naïve controls (n = 4/group). Regions of interest were drawn for several cortical (prefrontal, temporal, parietal, occipital and midcingulate) and subcortical (thalamus, amygdala and hippocampus) areas. Cortical SERT availability was significantly higher in monkeys with a cocaine self-administration history compared to controls whereas MDMA self-administration resulted in lower levels of SERT availability. These data extend our previous findings indicating that cocaine and MDMA self-administration differentially alter SERT availability in subcortical and cortical regions, which may have implications for development of treatment drugs.
可卡因自我给药主要改变中边缘脑区和前额叶脑区的多巴胺能和 5-羟色胺能功能,而 3,4-亚甲二氧基甲基苯丙胺(MDMA)自我给药则主要在更广泛的皮质区域改变 5-羟色胺能功能。我们之前的研究报告表明,与未接受药物的恒河猴相比,可卡因自我给药但不是 MDMA 自我给药与两个中边缘脑区(尾状核和壳核)中 5-羟色胺转运体(SERT)的可用性增加有关,这是通过使用 SERT 特异性配体 [(11)C]-3-氨基-4-(2-二甲氨基-甲基-苯基硫基)-苯甲腈 ([(11)C]DASB 的正电子发射断层扫描 (PET) 测量得出的。本研究的目的是将可卡因和 MDMA 自我给药之间的这种比较扩展到皮质区域的 SERT 可用性,先前的研究表明,人类药物滥用者的皮质区域受到影响,并且与执行功能有关。在有可卡因(平均摄入量= 742.6 mg/kg)或 MDMA(平均摄入量= 121.0 mg/kg)自我给药史的成年雄性恒河猴以及未接受药物的对照(每组 n = 4)中进行了使用 [(11)C]DASB 的 PET 研究。为几个皮质(前额叶、颞叶、顶叶、枕叶和中扣带回)和皮质下(丘脑、杏仁核和海马)区域绘制了感兴趣区域。与对照组相比,有可卡因自我给药史的猴子的皮质 SERT 可用性明显更高,而 MDMA 自我给药则导致 SERT 可用性降低。这些数据扩展了我们之前的发现,表明可卡因和 MDMA 自我给药以不同的方式改变皮质和皮质下区域的 SERT 可用性,这可能对治疗药物的开发有影响。